Tumor‐intrinsic CD21 expression impacts the response of B‐cell malignancy cells to CD19‐CAR‐T cells
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Leukocyte Biology"
DOI: 10.1002/jlb.5ma0122-474r
Abstract: CD19‐chimeric antigen receptor (CAR)‐based T‐cell therapy has produced promising clinical responses in patients with relapsed or refractory B‐cell malignancies. However, a significant portion of patients with mature B cell‐derived malignancies, including chronic lymphocytic leukemia (CLL)… read more here.
Keywords: cell; cd19 car; cells cd19; car ... See more keywords
CD19 CAR T Cells
Sign Up to like & getrecommendations! Published in 2017 at "Cell"
DOI: 10.1016/j.cell.2017.12.002
Abstract: CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome.… read more here.
Keywords: car cells; cell; car; cd19 car ... See more keywords
Beyond CD19 CAR-T cells in lymphoma.
Sign Up to like & getrecommendations! Published in 2021 at "Current opinion in immunology"
DOI: 10.1016/j.coi.2021.09.009
Abstract: Adoptive transfer of CD19-specific chimeric antigen receptor T-cells (CAR-T cells) has transformed the treatment paradigm of relapsed/refractory (R/R) CD19 B-cell malignancies, dramatically improving remission rates and cures in patients with chemo-refractory disease. However, the applicability… read more here.
Keywords: cd19; beyond cd19; car cells; cell ... See more keywords
Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.
Sign Up to like & getrecommendations! Published in 2020 at "Immunology letters"
DOI: 10.1016/j.imlet.2020.04.005
Abstract: In spite of impressive results in the treatment of acute lymphoblastic B cell leukemia (B-ALL) with chimeric antigen receptor (CAR) T cells, the clinical outcome of some hematological cancers like follicular lymphoma (FL) and chronic… read more here.
Keywords: a2ar; anti cd19; pharmacological targeting; car cells ... See more keywords
Prophylactic tocilizumab before CD3/4-1bb anti-CD19 car-T cell infusion decreases incidence of severe crs without increased risk of neurotoxicity
Sign Up to like & getrecommendations! Published in 2020 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2020.03.483
Abstract: Background & Aim Anti-CD19 CAR-T cells have demonstrated activity against relapsed/refractory lymphomas. Cytokine release syndrome (CRS) and CAR-T related encephalopathy syndrome (CRES) are well-known complications of CAR-T cell therapy. Tocilizumab, a humanized monoclonal antibody targeting… read more here.
Keywords: car cell; crs; anti cd19; car ... See more keywords
EVALUATION OF ANTI-CD19 CAR-T CELL PERSISTENCE AND EFFICACY USING A DEVELOPED MULTIPARAMETRIC FLOW CYTOMETRY AND QPCR TRACKING PLATFORM FOR PRECLINICAL AND CLINICAL STUDIES
Sign Up to like & getrecommendations! Published in 2021 at "Cytotherapy"
DOI: 10.1016/j.jcyt.2021.02.043
Abstract: Background Anti-CD19 chimeric antigen receptor (CAR)-expressing T cells have shown remarkable remission rates in acute B cell leukemias. It has been reported that anti-CD19 CAR-T cells sustain complete remission of leukemia even when their numbers… read more here.
Keywords: flow cytometry; anti cd19; cell; cd19 car ... See more keywords
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0831-z
Abstract: Despite high remission rates after CD19 CAR T-cell therapy in patients with refractory or relapsed B acute lymphoblastic leukemia (r/r B-ALL), relapses were commonly observed [1–4]. To improve long-term disease-free survival (DFS), our and other… read more here.
Keywords: cd19; tp53 mutation; therapy; car ... See more keywords
Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion
Sign Up to like & getrecommendations! Published in 2022 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-021-01554-w
Abstract: TO THE EDITOR: Acute lymphoblastic leukemia (ALL) is a clinically and genetically heterogeneous hematopoietic malignancy, and 75% of ALL cases in adults are of B-cell lineage [1]. The Ikaros protein plays a vital role in… read more here.
Keywords: cd19 car; treatment; car cell; cell ... See more keywords
Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1729735
Abstract: ABSTRACT Introduction: The success of CD19 chimeric antigen receptor (CAR)-T cell therapy for treatment of CD19 positive malignancies has led to the FDA approval of two CD19 CAR-T cell products, tisagenlecleucel and axicabtagene ciloleucel, and… read more here.
Keywords: car cell; car; neurotoxicity; cd19 car ... See more keywords
Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL.
Sign Up to like & getrecommendations! Published in 2020 at "Asia-Pacific journal of clinical oncology"
DOI: 10.1111/ajco.13474
Abstract: AIMS The purpose of this study was to design and manufacture CD19 chimeric antigen receptor (CAR)-modified T cells for clinical use in Thailand, as a model for how this technology can be directly applied at… read more here.
Keywords: leukemia; car cells; cell; car ... See more keywords
Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14638
Abstract: Ibrutinib might improve the efficacy of anti‐CD19 chimeric antigen receptor (CD19 CAR) T‐cell therapy in chronic lymphocytic leukemia (CLL). We studied the possibility and mechanism of the synergistic effect of ibrutinib and CAR‐T cells in… read more here.
Keywords: ibrutinib; car cells; car; synergistic effect ... See more keywords